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Abstract. Macrophage migration inhibitory factor (MIF) is
a pleiotropic pro-inflammatory cytokine, which possesses a
contributing role in cancer progression and metastasis and,
thus, is now considered a promising anticancer drug target.
Many MIF-inactivating strategies have proven successful in
delaying cancer growth. Here, we report on the synthesis of
ISO-66, a novel, highly stable, small-molecule MIF inhibitor,
an analog of ISO-1 with improved characteristics. The
MIF:ISO-66 co-crystal structure demonstrated that ISO-66
ligates the tautomerase active site of MIF, which has previously been shown to play an important role in its biological
functions. In vitro, ISO-66 enhanced specific and non-specific
anticancer immune responses, whereas prolonged administration of ISO-66 in mice with established syngeneic melanoma
or colon cancer was non-toxic and resulted in a significant
decrease in tumor burden. Subsequent ex vivo analysis of
mouse splenocytes revealed that the observed decrease in
tumor growth rates was likely mediated by the selective
in vivo expansion of antitumor-reactive effector cells induced
by ISO-66. Compared to other MIF-inactivating strategies
employed in vivo, the anticancer activity of ISO-66 is demonstrated to be of equal or better efficacy. Our findings suggest
that targeting MIF, via highly specific and stable compounds,
such as ISO-66, may be effective for cancer treatment and
stimulation of anticancer immune responses.
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Introduction
Macrophage migration inhibitory factor (MIF), a cytokine first
identified in 1966, is expressed fairly ubiquitously and has both
extracellular and intracellular roles (reviewed in ref. 1). MIF has
been implicated in auto-immune and infectious disease, and
cancer (reviewed in ref. 1). The causative role of MIF in cancer
progression was initially linked to its increased expression by
a variety of cancer cells, including prostate, colon, hepatocellular, lung, ovarian, in addition to melanoma, glioblastoma
and neuroblastoma (2). In these cancers, MIF overexpression
has been associated with a concomitant increase in: a) tumor
invasion/migration, b) metastasis and c) angiogenesis. More
recent data have additionally identified the role of the host
MIF in regulating tumor growth. In support of the latter, the
role of MIF in regulating tumor angiogenesis in the B16-F10
melanoma model has recently been investigated (3). A combination either of B16-F10 or of shRNA targeting of MIF in
the same melanoma cells with a MIF knockout (-/-) genetic
background, resulted in significant reduction of tumor growth
(by 47%), when compared to wild-type mice. Furthermore,
reduced growth of CT26 colon tumors (by 75%) in MIF-/mice was reported (4). Finally, host macrophage-produced
MIF was shown to polarize tumor-associated macrophages
(TAMs) towards an immunosuppressive M2 phenotype,
whereas MIF inhibition or gene loss (MIF-/-) reversed TAM
functionalities to M1-type (5). These studies, in conjunction
with the previous reports, establish MIF as a promising anticancer drug target.
An increase of MIF levels positively correlates with a poor
prognosis in cancer (6-8). Anti-MIF neutralizing antibodies
(Abs), MIF-directed siRNA/shRNA or antisense oligonucleotides and compounds hindering MIF secretion have been
tested in vitro and in preclinical models with notable results
(9,10). A more attractive approach to decrease MIF upregulation is the utilization of small molecule MIF inhibitors, which
advantageously block the activity of both cancer cell- and host
cell-secreted MIF. ISO-1, the ‘gold standard’ inhibitor of MIF,
was designed to selectively ligate the tautomerase catalytic
site of MIF which is known to neutralize its pro-inflammatory
activity (1,11,12). In vitro MIF reduction by ISO-1, has been
reported to effectively reduce cancer cell proliferation, migra-
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tion, and invasion of the human lung adenocarcinoma A549
(10,13) decrease the proliferation and invasiveness of prostate
cancer DU-145 cells (9), restore contact inhibition of proliferation of LN229 and LN-18 glioblastoma cells (14), reduce
cell migration and invasion of HS683 glioma cells (15), and
suppress the proliferation of the murine colorectal cancer
cells CT-26 (16). Previous studies have also addressed the role
of ISO-1 in prostate and colorectal cancer in vivo (9,16). In
both mouse models, ISO-1 treatment resulted in significant
reduction of the tumor volume or weight, despite the lack of an
optimal dosing regimen.
In our search for more effective MIF inhibitors, we herein
identify ISO-66, as a potent inhibitor of MIF. We show that
ISO-66 enhances the cytotoxicity of human lymphocytes
in vitro and when administered to mice with established
tumors (melanoma and of the colon), is effective in suppressing
tumor growth in vivo. We believe ISO-66 offers promise as
a MIF-reducing therapy in cancer and other MIF-implicated
diseases.
Materials and methods
Preparation of ISO-66. All solvents were HPLC-grade from
Fisher Scientific. Silica gel (Selecto Scientific, 32-63 µm
average particle size) was used for flash column chromatography (FCC). Aluminum-backed Silica Gel 60 with a 254-nm
fluorescent indicator TLC plates were used. Spots on TLC
plates were visualized under a short wavelength UV lamp or
stained with I2 vapor. NMR spectra were collected on a Jeol
Eclipse 400 spectrometer at 400 MHz for 1H NMR spectra
and 100 MHz for the 13C NMR spectra. Coupling constants
are reported in Hertz (Hz), and chemical shifts are reported
in parts per million (ppm) relative to deuterated solvent peak.
The coupling constants (J) are measured in Hertz (Hz) and
assigned as s (singlet), d (doublet), t (triplet), m (multiplet) and
br (broad). High-resolution mass spectra were carried out at
the Mass Spectrometry Facility at the Hunter College of the
City University of New York.
To a solution of 3-fluoro-4-hydroxybenzaldoxime (1 g;
6.45 mmol) in anhydrous DMF (120 ml) was added NCS
(1.03 g; 7.74 mmol). The reaction mixture was stirred for 5 h at
room temperature affording the chloro oxime. To this solution,
4-penten-2-one (1.0 ml; 9.7 mmol) (oxidize 4-penten-2-ol with
PCC in DCM) was added, followed by the dropwise addition
of triethylamine (1.34 ml; 9.68 mmol) in DMF (12 ml). The
reaction mixture was stirred under N2 at room temperature
for 48 h. The solvent was removed in vacuo and the residue
was taken up in EtOAc. The EtOAc solution was washed with
0.5 N HCl, water, brine, and dried with anhydrous MgSO4.
The filtrate was evaporated to dryness and the residue was
purified by FCC (hexane:EtOAc 4:3) to yield ISO-66 as a pale
yellow solid (0.6 g; 39%). 1H NMR (500 MHz, Methanol-d4)
δ 7.40 (d, 1H), 7.30 (d, 1H), 6.96 (m, 1H), 5.05 (m, 1H), 3.53
(m, 1H), 3.03 (m, 2H), 2.86 (m, 1H), 2.21 (s, 3H); 13C NMR
(125 MHz, Methanol-d4) δ 31.43, 42.08, 79.24, 116.07, 116.23,
119.85, 123.54, 125.70, 149.46, 152.76, 154.68, 158.84, 209.48;
HR-MS(ES) m/z (M+H) 238.0871 (found); 238.0873 (calculated). Compound KF III 53Y, the prodrug of ISO-66, was
prepared from the ISO-acid chloride with bis-trimethylsilyl
malonate via methods reported in the literature (17,18). KF III

53Y has better solubility than ISO-66, but undergoes fast
decarboxlyation to form ISO-66 upon formulation in buffer.
MIF tautomerase inhibition assay. MIF tautomerase
activity was measured using a UV-Visible spectrophotometer (Shimadzu, UV1600U). A fresh stock solution of
L-dopachrome methyl ester was prepared at 2.4 mM through
oxidation of L-3,4-dihydroxyphenylalanine methyl ester with
sodium periodate. One µl of MIF solution (800-900 µg/ml)
and 1 µl of a dimethyl sulfoxide (DMSO) solution with various
concentrations of the MIF inhibitor were added into a plastic
cuvette (10 mm, 1.5 ml) containing 0.7 ml assay buffer (50 mM
potassium phosphate, pH 7.2). Then, activated L-dopachrome
methyl ester solution (0.3 ml) was added to the assay buffer
mixture. Activity was determined at room temperature and
spectrometric measurements were made every 5 sec at λ =
475 nm for total 20 sec, by monitoring the rate of decolorization of L-dopachrome in comparison to a standard solution.
Crystallization and X-ray data collection. Recombinant
human MIF was expressed in E. coli and purified as described
(19). Briefly, cells were lysed using a French Pressure Cell,
the lysate was clarified by centrifugation, and the supernatant
liquid was filtered with a 0.22-µm filter. The filtered supernatant was purified by ion-exchange in 20 mM Tris (pH 7.5),
20 mM NaCl using a DEAE and an SP column connected in
series. MIF is found in the flow-through. Flow-through fractions were collected, and fractions containing pure MIF were
pooled and concentrated.
A stock solution of 1.2 mM MIF in 20 mM Tris (pH 7.5),
20 mM NaCl, and a stock of 0.10 M KF III 53Y (the carboxylated derivative/prodrug, of ISO-66) in DMSO were used to
prepare a solution of 1.1 mM MIF, 10 mM KF III 53Y, 18 mM
Tris (pH 7.5), 18 mM NaCl, 10% DMSO. The KF III 53Y
spontaneously decarboxylated non-enzymatically, forming
ISO-66. Crystallization was performed using the hangingdrop vapor diffusion method. Two µl of the MIF-ISO-66
complex was mixed with an equal volume of reservoir
comprised of 2 M (NH4)2SO4, 0.1 M Tris (pH 7.5), 3% isopropanol. Crystals grew in three to five weeks. X-ray diffraction
data were collected from a single crystal at station X29 of the
National Synchrotron Light Source at Brookhaven National
Laboratory. Crystal dimensions were ~0.40x0.25x0.23 mm.
Immediately prior to mounting the crystal, it was soaked
briefly in cryoprotective solution containing 2.25 M NaCl, 2 M
(NH4)2SO4, 50 mM Tris (pH 7.5). An ω-sweep of 100˚ of data
were collected with 1.0809 Å radiation. Data were processed
using HKL2000. Data collection statistics are presented in
Table I.
Structure determination. The program AMoRe was used for
molecular replacement. Protein coordinates from the complex
of MIF with OXIM-11 (20) was used as the search model.
Refinement was performed primarily using the program
CNS (21). Refmac5 was also used for refinement. Occupancy
refinement was performed using CNS. Refined occupancies were normalized so that the sum of the occupancies of
corresponding atoms was 1.0. A TLS model was employed
in the Refmac5 refinement. The initial TLS model was found
using the TLSMD web server. Manual manipulation of the
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Table I. Crystallographic statistics.
Integration and scaling
Space group	P3121
Unit cell
a = b = 95.46 Å, c = 104.55 Å,
		
α = β = 90˚, γ = 120˚
Resolution, Å (highest shell) 1.55 (1.61-1.55)
Unique reflections
79,934 (7,885)
Completeness, %
99.6 (99.2)
Redundancy
5.8 (5.3)
Avg. I/Avg. σ
33.2 (2.25)
Rmerge
0.058 (0.534)
Refinement
R (working)
R-free
RMS deviations
from idealitya
Bond lengths (Å)
Bond angles (˚)

19.9%
22.0%
0.010
1.273

Average B-factorsb, Å2
Overall
Protein (number of residues)
Water
Chloride
Sulfate
Inhibitors

25.577
24.061 (114x3 chains)
35.923 (281)
34.078 (6)
28.648 (1)
39.299 (4)

Calculated by Refmac5, using reference values from Engh and
Huber (43). bCalculated using the Baverage program in the CCP4
suite (CCP41994).
a

model was performed using O and COOT. The structure was
deposited into the RCSB Protein Data Bank. Crystallographic
statistics are presented in Table I.
Cell lines and culture conditions. The human FM3 (melanoma), HCT-116 (colorectal carcinoma), K562 (leukemia),
Daudi (Burkitt's lymphoma), and the murine B16-F1 (melanoma), CT-26.WT (colorectal carcinoma), YAC-1 (lymphoma),
WEHI 164 (fibrosarcoma) cell lines, peripheral blood mononuclear cells (PBMCs) and their subpopulations and mouse
spleen cells were cultured in RPMI-1640, supplemented
with 10% heat-inactivated fetal bovine serum (FBS), 2 mM
L-glutamine, 10 mM Hepes, 50 µM β -mercaptoethanol,
5 µg/ml gentamycin, 10 U/ml penicillin and 10 U/ml streptomycin (all from Lonza, Cologne, Germany) (thereafter
referred to as complete medium), at 37˚C, in a humidified 5%
CO2 incubator. ISO-66 was dissolved in DMSO at 50 mM,
aliquoted and stored at -20˚C. Serial dilutions of stock solutions were freshly prepared prior to their use.
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Cell isolation and separation. Buffy coats were collected from
7 healthy blood-donors. Prior to blood withdrawal, individuals
gave their informed consent according to the regulations
approved by the 2nd Peripheral Blood Transfusion Unit and
Haemorophilic Centre, ‘Laikon’ General Hospital Institutional
Review Board, Athens, Greece.
PBMCs were isolated by centrifugation over FicollHistopaque (Lonza) density gradient, resuspended in complete
medium or cryopreserved in FBS-10% DMSO for later use.
Purified natural killer (NK; CD56 +) cells were obtained
using an immunomagnetic isolation procedure. Briefly,
5-10x106 PBMCs were incubated for 15 min at 4˚C with 20 µl
of anti‑CD56 monoclonal Ab conjugated to magnetic beads
(Miltenyi Biotec, Auburn, CA, USA). CD56+ cells were isolated
by positive selection on an MS column (Miltenyi), according
to the manufacturer's instructions. Purity of the isolated
populations was tested by flow cytometry (FACSCalibur,
Becton-Dickinson, Mountain View, CA, USA), using FITCand PE-conjugated anti-CD3 and anti-CD56 monoclonal Abs
(BD Pharmingen, San Diego, CA, USA). In all cases, purity of
the NK population was >90%.
For lymphokine-activated killer (LAK) cell generation, PBMCs were seeded in 24-well plates (1x10 6 cells/
ml; 2 ml/well) and cultured for 5 days in complete medium
supplemented with 1,000 IU/ml recombinant human interleukin (IL)-2 (Proleukin, Roche, CA, USA). Culture medium
containing IL-2 was renewed every other day. On day 5, LAK
cells were harvested and tested as described.
Monocytes were isolated by seeding PBMCs in 6-well
plates (5x106/ml; 3 ml/well) and let adhere for 2 h at 37˚C. The
non-adherent cell fraction (comprising >80% CD3+ cells as
assessed by flow cytometry) was collected and cryopreserved
for later use in T cell stimulation cultures.
Proliferation assay. FM3, HCT-116, Β16-F1 and CT-26.WT
cancer cells were seeded into 96-well U-bottom microplates
(Costar, Cambridge, MA, USA; 20-25x103 cells/ml; 200 µl/
well) and pre-incubated for 24 h to adhere. ISO-66 was
serially diluted at various concentrations (1 mM-0.04 µM),
added to the wells and incubated for 72 h. All cultures were
set in triplicates, whereas cultures set in complete medium or
containing an equivalent amount of DMSO (2% v/v) or doxorubicin (0.5 µΜ; Sigma-Aldrich, Japan) were used as controls.
For the last 18 h, 3[H]-thymidine (Amersham Pharmacia
Biotech, Amersham, Bucks, UK) was added and inhibition of
proliferation was determined as described (22).
Stimulation of PBMCs, NK, LAK and T cells with ISO-66.
PBMCs were seeded in 48-well plates (1x106 cells/ml; 1 ml/
well), ISO-66 was added at final concentrations of 1 mM-1 µM
and cells were cultured for 3 days. PBMCs cultured in plain
complete medium served as controls. NK cells were isolated
by magnetic beads and used as effector cells (E) versus K562
(NK-sensitive) targets (T), in standard 51Cr release assays at an
E:T ratio of 10:1. Similarly cultured LAK cells were also used
as effectors versus K562 and Daudi (LAK-sensitive) targets at
an E:T ratio of 50:1.
T cells were stimulated with a pool of tumor antigenic
peptides, extracted from the cell surface of FM3 and HCT-116
[acid wash extract, AWE (25)], as previously described (23). In
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brief, on day 0 monocytes were irradiated at 30 Gy, washed and
co-incubated with autologous T cells, at a monocyte:lymphocyte
ratio of 1:5. AWE extracted from 20x106 FM3 or HCT-116
cells and ISO-66 at a final concentration of 10 µM, were added
to each well. Cultures set without ISO-66 served as controls.
On day 5, lymphocytes were restimulated with autologous
irradiated monocytes and FM3- or HCT-116-AWE. On days
2, 5, 7 and 9, IL-2 (40 IU/ml) and ISO-66 (10 µM) were added
to the culture medium. T cells were harvested on day 11 and
tested for their cytotoxic activity versus FM3, HCT-116 and
Daudi targets, using standard 51Cr-release assays, at an E:T
ratio of 50:1.
In vivo melanoma and colon cancer mouse models. Female
mice, 6-8 weeks of age, 15-20 g of weight, of the strains
C57BL/6 and Balb/C were purchased from Harlan Laboratories
(Udine, Italy). All mice were maintained under conditions and
protocols in accordance with Law 2015/27/2.1992, Presidential
Decree 160/3.5.1991 and the Directive 86/609/EEC/24.11.1986
of the Council of Europe on Animal Welfare. The study
was approved by the Ethics and Biosafety Committee,
Subcommittee on Ethics, Department of Biology, University
of Athens and all experiments were conducted following the
guidelines of the aforementioned committee.
B16-F1 (syngeneic to C57BL/6 mice) and CT-26.WT
(syngeneic to Balb/C mice) were expanded to sufficient
numbers in complete medium. On day 0, C57BL/6 and
Balb/C mice were subcutaneously (s.c.) inoculated with 1x105
B16-F1 or 1x10 6 CT-26.WT (in 250 µl PBS), respectively,
and mice of each strain were randomly assigned to 5 groups
(8 mice/group). On days 12-14, when tumors were palpable,
and for 20 consecutive days, mice received intraperitoneally
(i.p.) PBS or DMSO (control groups), or ISO-66 (all diluted in
300 µl PBS) once daily. ISO-66 was administered at 180 µg/
dose/animal. DMSO was administered at a final concentration of 4% v/v, equivalent to the amount present in ISO-66
injections. Tumor growth rate was recorded every 2-3 days
by measuring the major and minor axes of the tumors formed
with a digital caliper. Measurements were transformed into
tumor volume using the formula: tumor volume (cm 3) =
major axis x minor axis2 x 0.5. On days 34 (for C57BL/6)
and 40 (for Balb/C), when mean tumor volumes of the
control groups exceeded 1.5-2 cm3, animals were euthanized
and spleens were aseptically excised from 3 mice/group.
Splenocytes were isolated from individually homogenized
spleens and immediately tested for their cytotoxicity versus
B16-F1, CT-26.WT, YAC-1 and WEHI-164 targets in standard
51
Cr-release assays.
Cytotoxicity assay. Target cells (Τ) were 51Cr-labelled
according to Skopeliti et al (24) and co-cultured with the
effectors (Ε) at the indicated E:T ratios. After 18 h at 37˚C,
5% CO2, 100 µl of each supernatant was removed and isotope
was measured in a γ-counter (1275 Minigamma, LKB Wallac,
Turku, Finland). Targets were incubated with 3 N HCl and in
complete medium to determine maximal and spontaneous
isotope release, respectively. All cultures were set in triplicates.
Percentage of specific cytotoxicity was calculated according
to the formula: (cpm experimental - cpm spontaneous)/(cpm
maximal - cpm spontaneous) x 100.

Statistical analysis. Data were analyzed by the Student's t-test
and statistical significance was presumed at significance level
of 5% (p<0.05). Tumor size among groups was compared with
Wilcoxon's signed rank test.
Results
ISO-66 as an inhibitor of MIF. We have identified ISO-66,
a novel analog of ISO-1, as a potent inhibitor of MIF tauto
merase activity (Fig. 1). The rationale for the design of ISO-66
is based on our previous experience with ISO-1 design and
structure activity relationship (SAR) studies. For instance,
the ester functional group in ISO-1 has been shown to play
an important role in binding to MIF, as evident by SAR
studies and MIF: ISO-1 co-crystal structure (11). However,
the methyl ester may hydrolyze and this could limit future
application of ISO-1. We hypothesized that the methyl ester
could be replaced by a ketone group and came up with the
structure of ISO-66. ISO-66 was synthesized in three steps
and characterized by NMR and mass spectrometry. ISO-66
was found to inhibit MIF tautomerase activity with an IC50 of
1.5±0.4 µM compared to 18.2±.8 µM for ISO-1. It is superior
to ISO-1 in both its potency and stability profile. To improve
the solubility of ISO-66, the β -keto carboxylate was also
synthesized (referred to as KF III 53Y/prodrug of ISO-66);
however, it was found by mass spectrometry that KF III 53Y
spontaneously decarboxylates to form ISO-66. This finding
was also supported by structural studies, in which MIF was
co-crystallized with KF III 53Y.
Structure of MIF-bound ISO-66. ISO-66 was found bound
in the MIF tautomerase active sites, with the meta-fluoropara-hydroxyphenyl ring buried in the innermost part of the
cleft, as expected. What was unexpected, however, was that
the five‑membered ring of the inhibitor had been opened. The
bond between the nitrogen and oxygen was cleaved, resulting
in free imine and hydroxyl groups (Fig. 2). An open ring
structure was seen in all three active sites. Fig. 2 shows the
electron density for the inhibitor in active site C, in which
no active site residues participate in crystal contacts, clearly
revealing the absence of the five-membered ring. The electron
density is also shown for active site B, in which the density
is better defined due to the crystal contacts. The presence
of the modified (ring-opened) inhibitor in the active site
demonstrates that it is itself a potential inhibitor of MIF's
physiological activity.
Both non-polar and polar interactions occur between the
modified inhibitor and MIF. The m-fluoro-p-hydroxyphenyl
ring is buried in the hydrophobic cavity of the protein. The
hydroxyl group shares a hydrogen bond with Asn 97 at the base
of the cavity. The fluorine atom has Van der Waals contacts
with the side chain of Met 101 and the β-methylene group of
His 62. Electron density for the fluorine atom is only found on
one side of the ring (Fig. 2), demonstrating that the ring does not
stochastically flip between the two states 180˚ apart. Rotating
the ring by 180˚ would cause steric conflict between the Tyr 95
and the electronegative fluorine, which would point toward the
Tyr 95 aromatic π-orbital if the inhibitor's aromatic ring was
in such an orientation. Lys 32 donates a strong hydrogen bond
to the hydroxyl generated by the ring-opening reaction. The
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Figure 1. Synthesis of ISO-66 and IC50 in MIF tautomerase assay of ISO-1, ISO-66 and the prodrug of ISO-66 (ISO-1, 18.2±2.8 µM; ISO-66, 1.5±0.4 µM;
prodrug of ISO-66, 1.8±0.1 µM).

Figure 2. Crystallographic structure of modified ISO-66 bound to MIF. (A and B) The Fo-Fc electron density, calculated with the omission of all inhibitor
atoms, contoured at 2.5σ. (A) The fit of the inhibitor in the solvent-exposed active site (active site C). (B) The fit in active site B, which has better-defined
density, presumably due to crystal contacts. (C) Schematic representation of the hydrogen bonding interactions of modified KF III 53Y/prodrug of ISO-66 with
MIF. Numbers listed above are distances in Ångstroms from active site C, and the lower ones are those from active site B.
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Figure 3. Comparison of the binding of MIF with intact ISO-66 to that with the modified inhibitor. (A) Stereo view of the modified KF III 53Y/prodrug of
ISO-66, as bound in active site A. Shown is 2Fo-Fc electron density, omitting only the intact KF III 53Y/prodrug of ISO-66, contoured at 1σ. Note that, while
most of the inhibitor fits the electron density, the methyl ketone group does not fit properly. (B) The poor fit in (A) is explained by the presence of a partial
occupancy inhibitor with an intact five-membered ring. The electron density map is the same as shown in (A). (C and D) Comparison of the hydrogen bonding
interactions between the forms with the five-membered ring open (C) and closed (D) in active site A. Distances are in Ångstroms.

nitrogen that was formerly of the five-membered ring accepts
a hydrogen bond from the main chain amide of Ile 64.
In active site A, however, there was excess electron density
around the methylene and terminal methyl ketone group of
the inhibitor (Fig. 3A). It is very interesting that this excess
density can be explained by the intact, ring-closed form of the
inhibitor, having partial occupancy (Fig. 3B). Both the ringopened and ring-closed forms were modeled into the electron
density, having occupancies of 0.88 and 0.12, respectively. The
low occupancy of the intact inhibitor has no or little effect on
the electron density in the phenyl portion where the B-factors
for the modified inhibitor are lower than those of the intact
form. However, the higher B-factors on the methyl ketone side
of the modified inhibitor yields deterioration of the electron
density there, where we instead see the intact form. The intact
inhibitor also accounts for the extra breadth of electron density
located at the five-membered ring, as shown in Fig. 3.

Both the intact and modified forms of ISO-66 interact
with MIF in active site A. The interactions of the modified
compound with MIF in active site A are similar to those in
the other two active sites. The hydrogen bond between the
nitrogen of the ring-opened inhibitor and the Ile 64 backbone
amide is stretched (3.46 Å) relative to the other two active
sites. The binding interactions of intact ISO-66 with MIF
are as follows: Lys 32 donates a hydrogen bond to the oxygen
atom of the five‑membered ring and is also within hydrogen
bonding distance to the ring nitrogen. The phenyl ring is positioned in the MIF hydrophobic pocket, but does not fit as deep
into the cavity as the phenyl ring of the modified inhibitor.
The hydroxyl group of the phenyl ring of the intact inhibitor
ISO-66 shares a hydrogen bond with Asn 97. However, this is
not as strong as the hydrogen bond between Asn 97 and the
modified inhibitor (Fig. 3). This presents the structural view
of how ISO-66 binds to its target MIF, providing a means
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Figure 4. ISO-66 does not inhibit cancer cell proliferation. FM3, HCT-116, B16-F1 and CT-26.WT cells were incubated with various concentrations of ISO-66
(1 mM-0.04 µM), DMSO (2% v/v) and doxorubicin (Dox; 0.5 µM) for 72 h. The percentage of DMSO corresponds to the equivalent amount used to dilute
1 mM of ISO-66.

Figure 5. ISO-66 enhances NK and LAK cell cytotoxicity. (A) PBMCs were incubated for 3 days with ISO-66 (1 mΜ-1 µΜ), NK cells were purified and tested
as effectors against K562, at an E:T ratio of 10:1. *p<0.05 compared to (-). (B) LAK cells were incubated for 3 days with ISO-66 (10 µM) and tested as effectors
against K562 (left) and Daudi (right). The E:T ratio was 50:1. Data are mean cytotoxicities ± SD from 2-5 healthy donors. (-), cells incubated in plain medium.

for it to have the antitumor effects described in this report.
Furthermore, this suggests the open-ring form we discovered
through the crystallographic analysis could also be a potential
chemotherapeutic lead compound, which may be investigated
in future studies.
ISO-66 does not affect cancer cell proliferation in vitro. To
assess whether ISO-66 is directly cytotoxic to cancer cells, we
tested its effect in inhibiting the proliferation of the human and
mouse melanoma (FM3 and B16-F1) and colon cancer cells
(HCT-116 and CT-26.WT). In all experiments, the equivalent
amount of DMSO (2% v/v) present in the highest ISO-66
concentration tested (1 mM), and the chemotherapeutic drug
doxorubicin (0.5 µM) were used as controls. Our results
showed that low concentrations of ISO-66 did not affect the
proliferation of cancer cells, whereas at the highest ISO-66
concentration tested, an analogous inhibition of proliferation
(~50%) was also caused by the equivalent amount of DMSO
(Fig. 4).
ISO-66 enhances NK and LAK cell cytotoxicity. For assessing
the ability of ISO-66 to induce cytolytic PBMC responses
in vitro, we incubated normal donor-derived PBMCs with
1 mM-1 µΜ ISO-66 for 3 days and then we isolated the CD56+
cells from the cultures. Our titration experiment (Fig. 5A)
showed that NK cell cytotoxicity versus K562 cell targets was

equally enhanced by 16% upon incubation with 10 or 100 µΜ
ISO-66. We further generated LAK cells from PBMCs of
healthy donors and cultured them with ISO-66 for 3 days. In
the cytotoxicity test, we observed that ISO-66 increased LAK
cell cytotoxicity against K562 (36.5% for ISO-66, compared
to 23.5% of the control; Fig. 5B), which was further enhanced
when Daudi cells were used as targets (70.7% for ISO-66,
compared to 56.2% of the control; Fig. 5B). However, for both
targets, this increase in LAK cell cytotoxicity did not reach
statistical significance.
ISO-66 enhances T cell cytotoxicity. We next sought to investigate whether ISO-66 is able to enhance T cell cytotoxicity.
As specific antigen source for T cell stimulation, we used
a pool of tumor antigenic peptides, detached from MHC
molecules present on the surface of melanoma (FM3) and
colon cancer (HCT-116) cells. In the presence of autologous
irradiated monocytes as antigen-presenting cells, this extract
(AWE) has been already used by us (23) and others (25) to
generate in vitro tumor-reactive T cell lines. On day 5, T cells
were restimulated with autologous AWE-loaded monocytes.
To expand AWE-reactive T cells, low dose IL-2 (40 IU/ml)
was used. ISO-66 was added to the cultures every other day,
while cultures in plain medium served as controls. On day 11,
AWE-reactive T cells cultured in the presence of ISO-66 were
able to recognize and lyse more efficiently the targets used for
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Figure 6. ISO-66 enhances antigen-specific T cell cytotoxicity. T cells were twice stimulated with irradiated, FM3- (A) and HCT-116- (B) AWE-loaded
autologous monocytes, in the presence or absence of ISO-66 (10 µM). Recovered T cells were tested as effectors against FM3, HCT-116 and Daudi. The E:T
ratio was 50:1. Data are mean percentage cytotoxicity ± SD from 5 healthy donors. (-), cells incubated in plain medium.

AWE preparation (Fig. 6). Specifically, FM3-AWE-stimulated
T cells killed FM3 targets (58.4%) and this cytotoxicity was
enhanced in the presence of the MIF inhibitor (69.0%). The
same T cells marginally lysed allogeneic HCT-116 colon
cancer targets (<25%), but showed some LAK cytotoxicity
(36.1% against Daudi cells), which was higher when ISO-66
was added in the cultures (49.5%; Fig. 6A). Accordingly,
HCT-116-AWE-stimulated T cells killed HCT-116 targets
(44.6%) and ISO-66 increased this percentage to 68.5%.
HCT-116-AWE-stimulated T cells did not lyse FM3 targets
(<25%) and similarly to FM3-AWE-stimulated T cells, they
exhibited increased LAK activity as detected by their cytotoxicity against Daudi (45.0% for ISO-66, compared to 33.9% of
the control; Fig. 6B).
Although, the enhancement of cytotoxicity induced by
ISO-66 was in all cases not statistically significant compared
to unstimulated cells, we cannot rule out the possibility that
additional T cell stimulations could have resulted in a more
pronounced effect. Taken as a whole, our results show that
ISO-66 increases the specific and non-specific cytotoxic
responses of activated human T cells in vitro.
ISO-66 retards melanoma and colon tumor growth in vivo.
To test the anticancer activity of ISO-66 in vivo, mice were
implanted with syngeneic melanoma and colon cancer cells.
We specifically selected these two mouse models in order to be
able to compare our results on ISO-66 with already reported
data, in which MIF shRNA and ISO-1 were used to block
MIF in similar in vivo melanoma and colon cancer models,
respectively (3,16).
Following titration experiments (26), on day 0, C57BL6
and Balb/C mice received s.c. 1x105 B16-F1 or 1x106 CT-26.
WT cells (melanoma and colon carcinoma syngeneic cells,
respectively). By days 12-14, all mice had developed palpable
tumors and were further administered i.p. PBS, DMSO or
ISO-66 for 20 consecutive days. The dose of 180 µg ISO-66/
animal/day (3.6 mg/mouse) was based on previous reports on
the anticancer activity of ISO-1, where, although at different
time intervals, 3.2 mg (16) and 4 mg (9) per animal were i.p.
administered to tumor-bearing mice, without reported toxicity.

In contrast to these studies, in our protocols, we administered
ISO-66 daily and for 20 consecutive days, to significantly, if
not completely, inactivate MIF constantly produced both by
the host and by melanoma (27) or colon cancer cells (28).
Tumor growth was monitored until day 34 (for melanoma) or
day 40 (for colon cancer). As shown in Fig. 7A, tumor size
(expressed in cm3) in melanoma-inoculated mice treated with
ISO-66, showed a significantly slower increase as compared
to controls (i.e., mice receiving PBS or DMSO). On the 34th
day post-tumor cell inoculation, control mice were euthanized
for ethical reasons (tumor size ≥2 cm3), whereas the average
tumor volume recorded for animals treated with ISO-66
was 1.2 cm3. This tumor reduction of ~45% was statistically
significant (p<0.01, compared to controls).
For the colon cancer model (Fig. 7B), by day 40 post-inoculation, both control groups (i.e., mice receiving PBS or DMSO)
exhibited a similar rapid tumor development (≥1.5 cm3). The
therapeutic administration of the MIF inhibitor reduced tumor
growth rates in all animals of the ISO-66-treated group.
Specifically, the average tumor volume recorded for ISO-66
was 0.55 cm3, and this ca. 60% tumor volume reduction was
statistically significant compared to controls (p<0.001).
The in vivo antitumor responses induced upon treatment with
ISO-66 are mediated by T cells. To verify whether the in vivo
reduction of tumor growth was associated with increased antitumor immune responses induced by ISO-66, three mice from
each group that developed the smaller tumors were sacrificed
on day 34 for melanoma and on day 40 for the colon cancer
model. Without additional ex vivo stimulation, their splenocytes were used as effectors in 51Cr-release assays against
the murine NK-sensitive targets YAC-1, the LAK-sensitive
WEHI-164, and the syngeneic cells B16-F1 and CT-26.WT.
Splenocytes from ISO-66-treated melanoma-inoculated mice
were more efficient in killing B16-F1 targets than PBS- or
DMSO-treated mice (41.5 versus 11.7 and 11.9%, respectively;
p<0.01 compared to PBS; Fig. 8A). The same splenocytes did
not lyse the non-syngeneic CT-26.WT colon targets (10.8%),
or YAC-1 (13.0%), but showed some cytotoxicity against
WEHI‑164 (29.8% compared to 12.8% of the control; p<0.05).
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Figure 7. ISO-66 delays melanoma and colon tumor growth. C57BL/6 (A) and Balb/C (B) mice were s.c. inoculated with syngeneic B16-F1 (melanoma) and
CT-26.WT (colon cancer) cells, respectively, and i.p. treated with 180 µg/dose/mouse of ISO-66 for 20 consecutive days. Control mice received PBS (-) or
DMSO. Tumor growth was monitored for 34 days (A) and 40 days (B). Pooled data from 8 mice/group are shown. **p<0.01; ***p<0.001 compared to (-).

Figure 8. ISO-66 induces tumor-reactive immune responses in vivo. Mouse splenocytes were isolated on day 34 for the melanoma (A) and on day 40 for the
colon cancer (B) models and used as effectors versus CT-26.WT, B16‑F1, YAC-1 (NK-sensitive) and WEHI-164 (LAK-sensitive) target cells, at an E:T ratio
of 100:1. Data show mean specific cytotoxicity ± SD from spleen cells of 3 mice per group (see legend of Fig. 7), tested individually. **p<0.01 compared to (-).

These results indicate that the MIF inhibitor ISO-66 increased
the cytotoxicity of LAK cells and, most importantly, induced
the in vivo expansion of melanoma-reactive T cells.
Accordingly, spleen cells from mice bearing colon cancer
cells when treated with ISO-66, lysed the syngeneic CT-26.WT
targets (39.4% compared to 27.6% of the PBS group; Fig. 8B),
as well as the LAK-sensitive WEHI-164 (20% compared to
11.9% of the PBS group). Marginal cytotoxicity against the
melanoma B16-F1 and YAC-1 was recorded. Thus, from the
results obtained from both cancer models, we observe that
ISO-66 enhances tumor-reactive (T cell-mediated) and nonspecific (LAK cell-mediated) immune responses leading to
decreased cancer cell growth.
Discussion
MIF is a pleiotropic cytokine broadly studied in sepsis and
many infectious and auto-immune diseases (1). Recently, a
causative role in cancer progression has been attributed to
MIF, as it has been reported to inactivate p53 (29), enhance

angiogenesis (30), promote metastasis (31) and impair both
innate and adaptive immune responses (5,32-34). Therefore,
inactivating MIF provides an alternative therapeutic option
in anticancer treatment (11). Small-molecule inhibitors of
host- and cancer cell-derived MIF have been used to block
its activity (35). The most prominent MIF inhibitor, ISO-1, is
known to inhibit the proliferation/invasiveness of cancer cell
lines in vitro (9,10,13-16,36) and tumor growth and vascularization in vivo (9,16).
In this study, using the structure of ISO-1 as a scaffold,
we designed a novel, more potent and more stable MIF inhibitor. In our initial in vitro studies, we observed that ISO-66
did not affect human and mouse cancer cell proliferation,
even at concentrations as high as 1 mM. On the contrary,
ISO-66 induced the cytotoxic potential of distinct effector
cell populations with antitumor activity, namely NK and
LAK cells and cytotoxic T cells (CTLs) (37). Specifically,
NK cells purified from human PBMCs cultured with ISO-66
showed increased killing of tumor targets (K562) and LAK
cells generated with high concentrations of IL-2, when
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stimulated with ISO-66 efficiently lysed both K562 and
Daudi targets. Most importantly, in the presence of ISO-66,
tumor antigen-reactive CTLs generated in vitro, recognized
and effectively killed the relative tumor-antigen expressing
targets. Our results are in agreement with previous reports
showing that MIF hampers anticancer immunity by inhibiting tumor-specific CTL and NK cell activity (33,34). The
mechanisms responsible for this CTL deficiency, probably
include MIF-induced downregulation of receptors involved
in tumor cell recognition (34) and/or excess T cell activation, leading to cell death (33). MIF is also known to impair
the ability of NK cells to release cytolytic perforin granules
(32). Additionally, it has been suggested that MIF's effect is
optimally exerted on activated cells, whereas normal functions of resting cells evolve independently of MIF (9). Our
results are in agreement with this scenario, as NK, IL-2activated LAK cells and antigen-stimulated CTLs, increased
their cytotoxicity in the presence of ISO-66. Although ISO-1
has been reported to inhibit proinflammatory cytokine and
IFN-γ secretion by human PBMCs or subpopulations thereof
(38,39), the enhanced functional responses of NK, LAK and
CTLs as observed in our in vitro system, do not support such
an ISO-66-induced suppressive effect. More likely, ISO-66
acts by blocking the activity of MIF produced by host
macrophages, possibly also T cells, allowing effectors to
exert their lytic functionalities.
Translating our in vitro observations in vivo, the therapeutic anticancer activity of ISO-66 was tested in C57BL/6
and Balb/C mice inoculated with syngeneic melanoma B16-F1
and colon CT-26.WT tumor cells, respectively. In line with
similar doses of ISO-1 given by others (9,16), we observed
that injecting a total of 3.6 mg of ISO-66 per mouse was
well-tolerated and did not cause any adverse effects. Further,
it led to a statistically significant retardation of tumor growth
in both models (45% for melanoma and ca. 60% for colon
carcinoma, compared to controls). Although the therapeutic
protocol of the in vivo ISO-66 administration used in our
study differs from other regimens used to date in terms of
intervals between injections, our results are comparable with
previously reported data on the antitumor activity both of
ISO-1 and anti-MIF Abs. Specifically, He et al (16) recorded
a 25% inhibition of CT-26 colon tumors upon treatment with
either ISO-1 or anti-MIF Abs administered twice per week,
whereas Ogawa et al (40) reported a much higher inhibition
(55%) of the same tumor upon a more frequent (every other
day) treatment with anti‑MIF Abs. These data support our
rationale of maximizing MIF inactivation by injecting mice
with ISO-66 daily for 20 consecutive days. Of greater importance are the recent elegant studies of Girard et al (3) and
Choi et al (4) in which MIF-/- mice inoculated with B16-F10
melanoma and CT26 colon cancer cells, respectively, exhibited a 47% and 75% tumor reduction compared to wild-type
animals. Melanoma growth in wild-type mice given daily
ISO-66 (Fig. 7A) resembles that observed in MIF-/- mice (3).
Similarly, colon tumor growth in our model (Fig. 7B), greatly
coincides the growth recorded in MIF-/- mice (4). Therefore,
we can propose that repetitive, daily dosing of ISO-66 effectively reduces the cancer-promoting effects of MIF.
This was further confirmed upon analyzing the ex vivo
cytotoxicity of spleen cells from mice administered ISO-66

against the inoculated tumors. We used splenocytes from
3 animals per group with minimal tumor load, as these most
likely had developed the highest percentages of cytotoxic
effectors. Our results revealed that splenocytes from mice
therapeutically administered ISO-66 exhibited increased
specific lysis only of the syngeneic cancer cells, both for
melanoma and colon cancer. Although we also observed a
non-negligible percentage of non-specific cytotoxic responses
enhanced by ISO-66, these accounted for <50% of the syngeneic tumor cell killing. To our knowledge, our results for the
first time suggest that successful MIF inactivation in vivo by
ISO-66 leads to restoration of the impaired tumor-reactive
lymphocyte responses in cancer-bearing mice. Due to ethical
reasons (Guidelines of Ethics and Biosafety Committee) we
could not follow murine tumor growth for a prolonged period,
but based on our results we could safely speculate that ISO-66
administration would also lead to prolonged animal survival.
There are several advantages to using small molecules,
such as ISO-1 or ISO-66, to block MIF activity instead of
neutralizing Abs against MIF or its receptor (9,12,16,41). Smallmolecule inhibitors can be developed and synthesized via a
less complex and expensive process, are non-immunogenic
upon repetitive administration, are more mobile in reaching
their target and do not usually require intravenous injection
after formulation optimization [(12,42), and the present report].
Moreover, although administered at low concentrations, they
can still effectively and specifically target MIF irrespective
of its origin, i.e., whether deriving from host and/or cancer
cells. Indeed, in our study 9 mg/kg of ISO-66 was shown to
be non-toxic even after frequent administration and sufficient
to enhance in vivo tumor-reactive immune responses leading
to the reduction of tumor-cell expansion. In support of our last
assumption, Yaddanapudi et al (5) most recently reported that
the suicide inhibitor of MIF, 4-IPP, significantly slowed the
rate of B16 tumor growth, but to intracellularly block MIF
secretion by TAMs, 4-IPP was given at doses 10-fold higher
(80 mg/kg) than ISO-66 in our models, raising specificity
(35) and toxicity issues, if such high concentrations were to
be adapted for clinical use. In another study, the drug ibudilast
has been used in humans for two decades in the Far East for
bronchial asthma and post-stroke complication. It is an allosteric inhibitor of MIF at clinically relevant concentrations,
but its antitumor effect has yet to be studied (44).
Taken as a whole, our results in conjunction with accumulated evidence from other cancer studies, suggest that selective
MIF inactivation upon treatment with ISO-66 restores the lytic
ability of tumor-reactive CTLs and NK cells, which become
immunocompetent. These cells can further efficiently kill
tumor cells, thereby reducing the size of the tumors. Therefore,
anti-MIF therapies using improved small molecule inhibitors
selectively targeting MIF, such as ISO-66, may provide new
treatment options with the potential to complement currently
applied anticancer strategies.
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